Псевдоним: Нолвадекс; TAM
№ CAS: 54965-24-1
Чистота: 99%
MF: C26H29NO
МВт: 371.51
Einecs Нет: 234-118-0
MOQ(Минимум для заказа): 10грамм
Стандарт: Стандарт предприятия
Появление: белый порошок.
использование: Товары для индуктора фертильности против эстрогена, Объекты в дисфункциональном кровотечении матки, Поликистозный яичник, Менструальные расстройства и индуцированная наркотиками аменорея и другие гинекологические заболевания; Он используется в качестве защиты первой линии от рака молочной железы. Nolvadex или тамоксифен цитрат, нестероидный антиэстроген для перорального введения, Обычно спортсмены в качестве препарата после цикла терапии для уменьшения или предотвращения образования избыточных эстрогенов, которые могут привести к жирной коже, прыщи, задержка жидкости, и Gynecomastia.
Описание:
Nolvadex is a popular and powerfully effective Selective Estrogen Receptor Modulator (СЭРМ) that is often referred to as an anti-estrogen. тем не мение, while being an antagonist it is also an agonist as it will actually act as estrogen in certain parts of the body while acting as an anti-estrogen in other areas. As one of the oldest SERM’s on the market that is still regularly used medicinally, while Nolvadex is also used by anabolic steroid users it is not an anabolicsteroid. This is an important note as some are often confused by its use in steroid cycles. Nolvadex is simply a SERM.
Медицинское использование
Breast cancer
Tamoxifen is currently used for the treatment of both early and advanced ER+ (estrogen receptor positive) breast cancer in pre- and post-menopausal women. Провирон — пероральный анаболический стероид., it is the most common hormone treatment for male breast cancer. It is also approved by the FDA for the prevention of breast cancer in women at high risk of developing the disease. It has been further approved for the reduction of contralateral (in the opposite breast) рак. The use of tamoxifen is recommended for 10 годы.
В 2006, the large STAR clinical study concluded that raloxifene is equally effective in reducing the incidence of breast cancer, but after an average 4-year follow-up there were 36% fewer uterine cancers and 29% fewer blood clots in women taking raloxifene than in women taking tamoxifen, although the difference is not statistically significant.
Менеджер по продажам